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A new cysteine proteinase inhibitor, cystatin SN, was purified From human whole saliva by chromatography 
with DE32, Sephacryl S200, and CM-Sepharose CUB. Cystatin SN is immunologically related to cystatin 
S and both inhibitors have a similar molecular mass of about 13 kDa. The new inhibitor, however, was 
clearly distinguished From cystatin 5 by its much higher pZ value. These inhibitors showed similar inhibitory 
activity For ficin, but cystatin SN was a much better inhibitor For papain and dipeptidyl peptidase I. The 
amino acid sequence of cystatin SN deduced in the light of the known structure of cystatin S indicates that 
they have 10 different amino acid residues in the sequence comprising in total 113 residues. 
1. INTRCHXX’IION 
The structures of various cysteine proteinase in- 
hibitors of low Mr from animals have been 
elucidated [l-9]. According to the structural 
homology, cystatin S characterized by us [l] 
belongs to the extracellular type [2-51 which can 
be distinguished from the intracellular type [6-91. 
During the course of the study of this cysteine pro- 
teinase inhibitor of human saliva [ltlOI, we no- 
ticed the presence of several other proteins in saliva 
which cross-react immunologic~ly with cystatin S. 
One such protein could be separated well due to 
the difference in net charge. Here, we describe the 
characterization of this new cyst&e proteinase in- 
hibitor which we term cystatin SN because of its 
immunological cross-reactivity with cystatin S and 
its pl value near neutrality. 
2. MATERIALS AND METHODS 
Cystatin S was prepared as in IlI. Briefly, a 
reconstituted solution from lyophitized human 
whole saliva was mixed with DE32 pre-equilibrated 
with 0.02 M Tris-HCI (pH 7.5). The mixture was 
poured onto a column and washed with the same 
buffer. The column was then eluted with a linear 
gradient of NaCl (O-2%) in the buffer. Cystatin S 
was isolated from fractions eluted at NaCl concen- 
tration higher than 1%. Preparation of rabbit anti- 
cystatin S antiserum, chemical reagents and en- 
zymes used for sequence analysis and determina- 
tion of & values were as in fl,lOI. Carboben- 
zox~henyl~laRy1 - arginyl - methylconmarylamide 
(Z-Phe-Arg-MCA) was obtained from the Peptide 
Institute (Osaka), and glycyl-arginyl-methyl- 
coumarylamide (Gly-Arg-MCA) from E,Y. La- 
boratories. 
2.2. Methods 
M, values were estimated by SDS-poly- 
acrylamide gel efectrophoresis with a linear gra- 
dient of gel concentration from 10 to 20%. The 
isoelectric point was determined by isoelectric 
focusing on precoated ~Iyac~Iamide gel pfates 
~Ampholine Pagplate, LKB) with a pH range of 
3.5-9.5. 
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2.3. Enzyme assay 2.7. Amino acid sequence 
Papain and ficin were assayed ~uorimetrically 
with Z-Phe-Arg-MCA (111. Dipeptidyl peptidase I 
was assayed as described by Gounaris et al. [12] ex- 
cept that Gly-Arg-MCA was used as substrate in- 
stead of Gly-Phe-MCA. 
Amino acids were analyzed with an amino acid 
analyzer (Waters) and sequence analysis using 
manual Edman degradation was performed as in 
ill. 
2.4. Determination of protein and Ki values 3. RESULTS 
A sample was dissolved in water and the absor- 
bance at 280 nm measured. Molar absorption 
coefficients were calculated from the protein con- 
tent which was determined with a protein assay kit 
(Bio-Rad) using bovine serum albumin as standard 
and by assuming the molecular mass to be 13 kDa. 
3.1. Isolation of cystatin SN 
Cystatin SN was isolated from the fractions as 
indicated in fig.1. The preparation gave a single 
lui values were obtained from Dixon plots [ 13f. 
2.5. Isolation of cystatin SN 
Lyophilized, pooled whole saliva was 
reconstituted to the original volume and stirred 
overnight at 4°C [l]. Insoluble materials were 
removed by centrifugation. The supernatant was 
poured onto DE32 equilibrated with 0.02 M Tris- 
HCl (pH 7.5) in a glass filter. An unadsorbed frac- 
tion was collected and concentrated by ultrafiltra- 
tion using YM 5 membranes (Amicon) and then 
applied onto a Sephacryl 5200 column (1.7 x 
130 cm) equilibrated with 0.01 M NHeHCO3. 
Fractions having both inhibitory activity and im- 
munoreactivity with anti-cystatin S antiserum were 
lyophilized and dissolved in 0.02 M phosphate 
buffer (pH 6.8). The solution thus obtained was 
then applied onto a column of CM-Sepharose 
CL6B (fig. 1). 
, 
2.6. Peptide fragmentation and separation 
Reduced and carboxymethylated (Rem) cystatin 
SN was digested with mouse submaxillary gland 
protease or with Ac~romo~acter lysylendopep- 
tidase as in [l]. Peptides precipitating from the 
reaction mixture after lysylendopeptidase digestion 
of Rem-cystatin SN were collected by centrifuga- 
tion and further digested with trypsin at 25°C for 
6 h in 0.01 M NH4HCO3. Peptides obtained by 
these procedures were fractionated on a column of 
DEAE-Sepharose CL6B (0.7 x 24 cm) with linear 
gradient elution using 100 ml each of 0.01 M 
NH4HC03 and 1 M NHdHC03, and by reverse- 
phase high-performance liquid chromatography 
on a column of Synchropack RP8 (Synchrom) with 
acetonitrile in 5 mM phosphate buffer, pH 6.8. 
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Fig.1. Purification of cystatin SN on a CM-Sepharose 
CL6B column (1.8 x 40 cm). A sample solution derived 
from a saliva fraction which was unadsorbed to DE32 
was applied onto a column pre-equilibrated with 20 mM 
phosphate buffer (pH 6.8), and the column eluted with 
the same buffer. Fractions indicated by a bar showed 
reactivity with anti-cystatin S antiserum. Cystatin SN 
was obtained from fictions 32-36. Fractions were 
monitored for absorbance at 280 nm (+--o) and 
inhibitory activity (T---T) by using a 1Orl aliquot of 
each fraction and 23 ng ficin. 
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Fig.2, Electrophoretic analysis of cystatin SN in 
isoelectric focusing gel with a pH range of 3.5-9.5. (a) 
Cystatin SN, (b) unfractionated whole saliva, (c) cys- 
tatin S. 
band on isoelectric focusing gel electr~phoresis 
and was distinguished from cystatin S (fig.2). 
Table 1 fists the A& estimated by SDS gel elec- 
trophoresis, isoelectric point, molar absorption 
coefficient and iui values for ficin, papain, and 
dipeptidyl peptidase I in comparison with those of 
cystatin S. 
Cystatin SN and cystatin S gave precipitin lines 
forming a spur with anti-cystatin S antiserum in 
the double immunodiffusion system, indicating 
their partial identity (fig.3). The final yield of 
cystatin SN was 4.4 mg from f 1 whole saliva. 
The N-terminaf 23 residues were determined 
with Rem-cystatin SN (fig.4). Since a minor se- 
quence (about 25%) starting with isoleucine and 
running one residue ahead of the main sequence 
could be followed after the second step and 
thereafter, it was suggested that this preparation 
contained a poiypeptide lacking one of two 
isoleucine residues in the N-terminus. However, 
subsequent sequence studies with peptides derived 
by protease digestions (see below) suggested that 
cystatin SN was homogeneous except for the N- 
terminus. 
b 
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Fig.3. Double immunodiffusion analysis of cystatin SN. 
Rabbit a~t~~cystatjn S serum (central well) was allowed 
to diffuse against cystatin SN (l&ag per well) in welts 
(a), and cystatin S (3. f Fg per well) in wells (b). 
When Rem-cystatin SN was digested with mouse 
submaxillary gland protease, peptides MI-M7 
were obtained. Peptides M2-M4, M6 and M7 were 
completely sequenced, but peptides Ml and MS 
only partially (fig.4). 
When Rem-cystatin SN was digested with 
lysylendopeptidase, peptides Ll-L6 were obtained 
in a soluble form. The central part of the molecule 
(33-68) was obtained as a precipitate. Therefore, 
the precipitate was further digested with trypsin to 
yield soluble peptides LTI-LT6. These lysylen- 
dopeptidase peptides and IysyIendopeptidase- 
trypsin peptides were sequenced as shown in fig.4. 
The determined amino acid sequences of Rcm- 
cystatin SN and its proteolytic fragments were suf- 
ficient to explain the whole molecule on the basis 
of the amino acid composition. 
In view of the immunologi~l cross-reactivity of 
cystatin SN with cystatin S (fig.31, one can expect 
that these proteins have highly homologous struc- 
tures. Thus, in the light of the amino acid sequence 
of cystatin S [If, the proteolytic fragments of Rcm- 
Table f 
Some characteristics of cystatin SN and cystatin S 
1M, Pf E%nm, I cm 
(x 104) 
Ficin 
Cystatin SN 13000 7.5 1.8 44 
Cystatin S 13OW= 4.68 2.0 4.2 
’ The calculated value from the determjned sequence was 13 268 
K (nM) 
Papain Dipeptidyl 
peptidase I 
21.4 26.3 
108.2 > 630.2 
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A<p 10 20 > 30 
Ile-Ile-P~o-Gly-Gly-Ile-Tyr-Asn-Ala-Asp-Leu-Asn-Asp-Glu-Trp-Val-Gln-A~q-Ala-Leu-Hls-~he-Ala-Ile-Ser-Glu-Tyr-A5n-LyS-Ala- 
~___-___------____---_----_-_L~___----_--_-_-_-__-_-_-___-_-_-_-__-__-__--(~ 
+-----__--__-_-----__ Ml ----- ---------_, M2 
c,fu i,fu 40 I,,U i:! li Phz fi0 
Thr-Lys-Asp-Asp-Tyr-Tyr-Rrg-Arg-Arg-Pro-Leu-Arg-Val-Leu-Arg-Al~-Arg-Gln-Gln-Thr-V~l-Gly-Gly-Val-Asn-~r-Fhe-Phe-ASp-Val-Glu- 
L2----i I_LTl ----_I,--_ LT2 ___i,__LT3 __I~__LT4_~C_--_------- --- LTS-- - -- -_--__ 
ii- M3 ----if--- M4 -_I[ 
70 Xl1 90 
Val-Gly-Arg-Thr-Ile-Cys-Thr-LyS-Ser-Gln-P~o-Asn-Leu-Asp-Thr-Cys-Ala-Phe-Hl5-Glu-Gln-PrO-Gll~-Leu-Gln-LyS-LyS-Gln-LeU-CyS- 
_-__ --II-----LT~ +I L3 I-L4it------ 
-----_--__-I-__--_ ~',_____----_-_----_---__-------_ 
100 A%,> 'I++ n-r, Ill1 Aid 
Sex-Phe-Glu-Ile-Tyr-Glu-val-Pro-Trp-Glu-As~~-Arg-Arq-S~r-Leu-Val-Lys-Ser-Arg-Cys-Gln-Glu-Se~ 
L5 __-------- +i-----L6+ 
__-__---_---_---__ - - _1\-i%+t---------_ E27 -1 
Fig.4. Amino acid composition and sequence of cystatin SN. Composition: Asp + Asn 12.5 (6 + 6), Thr 4.8 (5), Ser 
5.6 (6), Glu + Gin 17.0 (9 + 8), Pro 5.6 (5), Gly 5.8 (S), Ala 6.8 (6), l/2 Cys 3.4 (4), Val 7.5 (8), Be 4.2 (6)*, Leu 7.5 
(8), Tyr 4.8 (6), Phe 4.7 (5), His 1.9 (2), Trp - (2), Lys 6.0 (6), Arg 9.3 (IO). Total 113 residues; &f, 13 284; an asterisk 
indicates that a discrepancy between experimental and calculated values may be due to the incomplete hydrolysis of the 
Ile-Be bond at the N-terminus. Numbers in parentheses are those from the composition determined after sequence 
analysis. The arrow above the sequence indicates the residues determined by Edman degradation of Rem-cystatin SN. 
Bars beneath the sequence denote the fragments used for the sequence study which were obtained by cleavage with 
mouse submaxillary gland protease (Ml-M7), lysylendopeptidase (LI-L6), and lysylendopeptidase plus trypsin 
(LTl-LT6). A solid part in a bar represents the sequenced part. The residues of cystatin S which differ from those of 
cystatin SN are shown above the corresponding residues of cystatin SN. 
cystatin SN were placed in order as shown in fig.4. 
The amino acid compositions of the peptides 
which were isolated but not sequenced (fig.4) 
agreed with this structure completely. 
4. DISCUSSION 
Although cystatin SN was clearly separated 
from cystatin S by ion-exchange chromatography 
because of their difference in isoelectric point, 
these two saliva proteinase inhibitors showed im- 
munological cross-reactivity which suggested their 
homologous structures. On the basis of this ex- 
pected structural similarity and the determined 
amino acid sequences of polypeptides, a tentative 
amino acid sequence of cystatin SN was proposed 
as in fig.4. The structure indicates that cystatin SN 
has a sequence with 10 amino acid substitutions 
from that of cystatin S. These 10 residues in- 
troduce 9 positive net charges into cystatin SN, 
which explains the fact that the pI value of this in- 
hibitor is much higher than that of cystatin S (table 
1). In addition, these substitutions seem to be 
responsible for the stronger inhibitory activity for 
148 
papain and dipeptidyl peptidase-I compared with 
cystatin S (tabie I). 
Our preliminary study has indicated that there is 
another inhibitor which is cross-reactive im- 
munologically with cystatin S but has an amino 
acid sequence distinct from both cystatin S and 
cystatin SN. Therefore, human saliva appears to 
contain several cysteine proteinase inhibitors 
which are related to cystatin S but different from 
cystatin S in inhibitory specificity due to different 
structures. 
REFERENCES 
(11 Isemura, S., Saitoh, E. and Sanada, K. (1984) J. 
Biochem. 96, 489-498. 
[2] Grubb, A. and Lofberg, H. (1982) Proc. Natl. 
Acad. Sci. USA 79, 3024-3027. 
[3] Turk, V., Brzin, J., Longer, M., Ritonja, A. and 
Eropkin, M. (1983) Hoppe-Seyler’s Z. Physiol. 
Chem. 364, 1487-1496. 
[4] Schwabe, C., Anastasi, A., Crow, H., McDonald, 
J.K. and Barrett, A.J. (1984) Biochem. J. 217, 
813-817. 
Volume 198, number 1 FEBS LETTERS March 1986 
[5] Hirado, M., Tsunasawa, S., Sakiyama, F., [9] Ritonja, A., Machleidt, W. and Barrett, A.J. 
Niinobe, M. and Fujii, S. (1985) FEBS Lett. 186, (1985) Biochem. Biophys. Res. Commun. 131, 
41-45. 1187-l 192. 
[6] Takio, K., Kominami, E., Wakamatsu, N., 
Katsunuma, N. and Titani, K. (1983) Biochem. 
Biophys. Res. Commun. 115, 902-908. 
[7] Machleidt, W., Borchart, U., Fritz, H., Brizn, J., 
Ritonja, A. and Turk, V. (1983) Hoppe-Seyler’s Z. 
Physiol. Chem. 364, 1481-1486. 
[8] Takio, K., Kominami, E., Bando, Y., Katsunuma, 
N. and Titani, K. (1984) Biochem. Biophys. Res. 
Commun. 121, 149-154. 
[lo] Isemura, S., Saitoh, E., Ito, S., Isemura, M. and 
Sanada, K. (1984) J. Biochem. 96, 1311-1314. 
[ll] Barrett, A.J. (1980) Biochem. J. 187, 909-912. 
[12] Gounaris, A.O., Brown, M.A. and Barrett, A.J. 
(1984) Biochem. J. 221, 445-452. 
[13] Dixon, M. and Webb, E.C. (1979) in: Enzymes, 3rd 
edn, pp.332-380, Longmans, London. 
149 
